...
....
Pharmaceutical
Biotechnology

> See specialized channels
Medical Devices & Diagnostics
> See specialized channels
Industrial
Biotechnology
> See specialized channels


  Join us

  Follow us on Twitter   Join our LinkedIn Group   Our Blog

Biotech News App
Provides access to the latest biotech press releases ...more

Android_Logo App Store RIM_Logo_small

Media Partnership:
Want to have your RSS feed integrated on our website? Contact us
RSS Feeds RSS Feeds
JoomlaWatch Stats 1.2.9 by Matej Koval
For Editors
Sign up for press releases
For Companies
Sign up for our newsletter
Back to PRESS RELEASES - 

CT Atlantic AG to Present Positive Preclinical Results for NY-ESO-1 HD-MAB at Forthcoming AACR Annual Meeting

| Print |
Tuesday, 05 April 2011 14:33 (UTC + 2)

CT_Atlantic_Logo

Zurich-Schlieren, Switzerland, April 5, 2011 / b3c newswire /- CT Atlantic AG, a biotech company focused on the identification and development of human-derived monoclonal antibodies (HD-MAB®) as novel therapeutics for the treatment of cancer, today presented preclinical proof of concept data for its lead HD-MAB® CTA001.12D7 that support its advancement into clinical development for the treatment of cancer.

In vivo studies demonstrated that CTA001.12D7 — the first human-derived antibody against cancer-testis (CT) antigen NY-ESO-1 — efficiently inhibits the growth of tumors in mice acting synergistically with chemotherapy. The results from these studies will be presented at the AACR Annual Meeting in Orlando, Florida on April 5th, 2011. “Based on its novel mechanism of action, CTA001.12D7 supports the patient’s ability to generate long-term anti-tumor immunity,” commented Dr. Martin Treder, CSO of CT Atlantic AG.

CTA001.12D7 was rescued from a melanoma patient with a favorable clinical course and was subsequently characterized in vitro and in vivo. CTA001.12D7 is a high affinity, functionally active antibody with a favorable pharmacokinetic profile. In vivo efficacy of CTA001.12D7 was associated with enhanced anti-tumor immune responses, suggesting that it exerts its anti-tumor effects through a novel mechanism termed Antibody-Facilitated T cell Induction in Cancer (AFTIC™).

Prof. Alexander Knuth, scientific founder of CT Atlantic AG and Chairman of the Department of Oncology, University Hospital Zurich, commented: “These exciting data for CTA-001.12D7 suggest that targeting of intracellular CT antigens such as NY-ESO-1 with specific antibodies has great potential for defining a new therapeutic class in cancer medicine.”

Time schedule and venue for the presentation at the AACR 2011 meeting:

Date & Time:

Tuesday, April 5, 2011 – 3:20 to 3:35 pm EDT

Title:

“Therapeutic efficacy of a human-derived antibody against cancer-testis antigen NY-ESO-1”

Location:

Room W224 A/B/E/F, Orange County Convention Center

Session Title:

Poised for the Clinic: Next Generation of Cancer Immunotherapy

Session Category:

Immunology

About NY-ESO-1
NY-ESO-1 is the best characterized and most immunogenic of the CT antigens. It shares the typical, tumor-restricted expression pattern of CT antigens with frequent abundance in a variety of malignancies including breast, bladder, prostate, skin, lung and hepatocellular carcinomas.

About CT antigens
Cancer-testis (CT) antigens comprise more than 100 intracellular proteins which can be subdivided into more than 44 distinct CT antigen families. CT antigens are virtually not expressed in normal tissues except germ cells, but can frequently be found in cancers where their abundance increases with higher clinical stages.

About CT Atlantic AG - www.ct-atlantic.com Atlantic AG is a biotechnology company focused on the identification and development of human-derived antibodies for the treatment of cancer. Founded in 2008, CT Atlantic AG is a spin-off from the University of Zurich, Switzerland, and the Ludwig Institute for Cancer Research (Zurich, Switzerland and New York, USA). The company is located in Zurich-Schlieren, Switzerland.
CT


Contact
CT Atlantic AG
Prof. Michael Höcker, MD
CEO
Wagistrasse 14
CH-8952 Schlieren
Switzerland
Tel: +41 (0) 44 731 94 00
This e-mail address is being protected from spambots. You need JavaScript enabled to view it